

In The Claims

Please amend the claims as follows:

1. (currently amended) A combined cosmetic or therapeutic preparation having a carrier system comprising membrane-forming lipids and having a triple combination of active ingredients, wherein at least one microcirculation-promoting substance and at least one active ingredient which is selected from

(a) at least one active ingredient is selected from anti-coagulants, ~~and~~

(b) at least one active ingredient is selected from vasoprotective agents, and

(c) at least one active ingredient is a vasodilatory microcirculation promoting substance selected from the group consisting of caffeine, nafidofuryl, pentoxifyllin, buflomedil, and ginkgo active ingredients.

2-5. (canceled))

6. (previously presented) A combined preparation according to claim 1 wherein the carrier system is vesicular.

7. (previously presented) A combined preparation according to claim 1 wherein the membrane-forming lipids include the groups of phospholipids, ceramides and diacylglycosides.

8. (previously presented) A combined preparation according to claim 1 wherein the membrane-forming lipids contain at least 70 % by weight of phosphatidylcholine.

9-10. (canceled)

11. (currently amended) A combined preparation according to claim 1 ~~2~~ wherein the vasoprotective agent is selected from aescin, rutin, diosmin, ruscogenin and mixtures thereof.

12. (previously presented) A combined preparation according to claim 11 wherein it contains aescin as the vasoprotective agent in an amount of 0.1 – 7 % by weight.

13. (previously presented) A combined preparation according to claim 1 wherein the microcirculation-promoting substance is selected from caffeine, naftidrofuryl, pentoxifyllin, buflomedil and ginkgo active ingredients and mixtures thereof.

14. (previously presented) A combined preparation according to claim 1 wherein it contains caffeine as the microcirculation-promoting substance in an amount of 0.1 - 2 % by weight.

15. (canceled)

16. (previously presented) A combined preparation according to claim 1 wherein the carrier system additionally contains linoleic acid in stabilised form in an amount of 2.5 to 4.5 % by weight.

17. (previously presented) A combined preparation according to claim 1 wherein the preparation further contains at least one thermoreceptor-agonist which is selected from the group consisting of natural or synthetic capsaicin in an amount of 0.1 to 1 % by weight and nicotinic acid, nicotinic acid amide, nicotinic acid ester or mixtures thereof in an amount of 0.5 to 5 % by weight.

18. (previously presented) A combined preparation according to claim 1 wherein the preparation further contains 10 – 25 % by weight of ethanol.

19-20. (canceled)

21. (previously presented) A combined preparation according to claim 11 wherein the microcirculation-promoting substance is selected from caffeine, naftidrofuryl, pentoxifyllin, buflomedil and ginkgo active ingredients and mixtures thereof.

22. (previously presented) The combined preparation of claim 21 where the microcirculation promoting substance is caffeine and the vasoprotective agent is aescin.

23 (previously presented) A combined preparation according to claim 22 wherein the preparation contains aescin in an amount of 4.0 to 6.0 % by weight and caffeine in an amount of 0.5 to 1.5 % by weight.

24. (new) A combined preparation according to claim 1 wherein the anti-coagulants are selected from heparins, fucoidans, hirudins, pentapeptides, coumarin derivatives and mixtures thereof.

25. (new) A combined preparation according to claim 24 wherein the anti-coagulant contains low molecular weight fucoidan in an amount of 0.1 – 10 % by weight.

26. (new) A combined preparation according to claim 1 wherein the preparation contains aescin in an amount of 4.0 to 6.0 % by weight, low-molecular fucoidan in an amount of 1.0 to 3.0 % by weight and caffeine in an amount of 0.5 to 1.5 % by weight.

27. (new) A method for the production of a preparation cosmetic or drug according to claim 1, for prophylaxis and/or treatment of hematomas comprising combining membrane-forming lipids and

(a) at least one active ingredient is selected from anti-coagulants,

(b) at least one active ingredient is selected from vasoprotective agents, and

(c) at least one active ingredient is a vasodilatory microcirculation promoting substance selected from the group consisting of caffeine, nafidofuryl, pentoxifyllin, buflomedil, and ginkgo active ingredients.

28. (new) The method for prophylaxis or treatment of hematomas of the lower eyelid, and/or veins comprising applying the preparation of claim 1.